Biosimilars of pembrolizumab

Biosimilares/General | Posted 14/10/2022 post-comment0 Post your comment

Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).

Cancer image015

The originator product, Merck Sharp & Dohme’s Keytruda (pembrolizumab), was approved by the US Food and Drug Administration (FDA) on 4 September 2014 and on 17 July 2015 by the European Medicines Agency (EMA) [1]. Keytruda had worldwide sales of US$14.4 billion in 2020, making it a lucrative target for biosimilars developers, see Table 1.

The patents on Keytruda expire in the US in November 2036 and in Europe on 13 June 2028 [1]. Some of the pembrolizumab biosimilars and non-originator biologicals* approved or in development are presented in Table 1.

Table 1: Biosimilars and non-originator biologicals* of pembrolizumab approved or in development
Company name, Country Product name Stage of development
BioXpress Therapeutics, Switzerland - In pipeline
DM Bio, South Korea - In pipeline
Formycon - In pipeline
NeuClone/Serum Institute of India, Australia/India - Preclinical. NeuClone and Serum Institute of India have agreed to co-develop 10 biosimilar monoclonal antibodies.
PlantForm/PlantPraxis Biotecnologia/ Bio-Manguinhos/ Fiocruz (ANVISA, Brazilian Health Regulatory Agency), Canada/Brazil* - In pipeline
*See editor’s comment.


Editor’s comment
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘biosimilares’ approved in Brazil might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related articles
Forwards for Formycon’s Keytruda and backwards for Prestige’s Herceptin

Preparing for future biosimilar opportunities


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Derbyshire M. Patent expiry dates for biologicals: 2018 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31. doi:10.5639/gabij.2019.0801.003

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: EMA, MSD, US FDA

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010